A data-grounded diagnosis of where the US deer-placenta opportunity really sits — built from EINNALAB’s own 16-month Search Console data, the live site, and the current US search results — with an exact recovery and conversion plan.
The site is not losing a race it was winning — the honest picture is more useful than that. In the US your average ranking has held and even improved over the last few months; what has shrunk is reach (how many searches you appear for). Underneath that sit two big, fixable levers: (1) the site is competing against itself — Google shows a weak page (position 19) for deer-placenta searches while the page that actually ranks well (position 4) stays invisible; and (2) almost all the traffic you earn lands on articles with no way to buy — a large, unclaimed pool of ready readers walking away. The bare phrase “deer placenta” is the wrong scoreboard (its US results are a wall of research papers and marketplaces). The right game — the buying cluster you already hold page-1 spots on, plus a conversion layer that captures the article traffic — is very winnable, and most of the work is not something the client can do alone.
| The assumption | What EINNALAB’s own data actually says |
|---|---|
| “We used to be #1 in the US for deer placenta.” | The bare US term has averaged position 27.77 (page 3) across the full 16 months. The real #1 was the brand name (position 1.01) — that’s the ranking being remembered. |
| “Our rankings dropped.” | Average position improved over recent months. What fell is reach (fewer searches shown for) — a different, and more fixable, problem than losing rank. |
| “We just need to be #1 for ‘deer placenta’.” | That single phrase returns mostly research papers + Amazon/eBay/iHerb — position 1 is a scientific article. It’s not a brand-winnable slot, so it’s the wrong target. |
| “The traffic just isn’t converting.” | Correct — because 98.6% of deer-placenta traffic lands on articles with no buy path. The offer works (branded visitors convert at 47%); the article reader simply has nowhere to act. |
Straight from EINNALAB’s US Search Console export. The bars are how often you appeared (reach); the line is your average rank (higher on the chart = better position). Reach dropped hard — but rank did the opposite. That single picture reframes the whole conversation.
US appearances fell from a ~2,640/mo peak to ~720/mo. Fewer searches surface the brand — the problem to solve is visibility breadth, not lost rank.
Average US position improved (Feb 12.0 → May 8.1). The pages you show for rank better now — there are simply fewer of them being served.
Six reasons, highest-impact first. Each is tied to a real number from the data or the live site. Together they explain the ceiling — and every one is a lever we can pull.
For deer-placenta searches Google serves the homepage (US position 19.6, page 2) and the articles — not the product page /deer-placenta-30000mg/, which already ranks a strong position 4.5 but is shown almost never. The asset that could win is invisible; a weaker page soaks up the demand it can’t convert. Untangling which page ranks for what (canonical + internal-link + content architecture) is expert, ongoing work — not a toggle.
Even with everything perfect, the exact phrase can’t be owned by a brand. The US top 10 is roughly 9/10 non-displaceable — scientific papers (position 1 is a research article), marketplaces (Amazon, eBay, iHerb) and a government advisory. Aiming the whole strategy at this one term guarantees a scoreboard that never reads “win.”
Roughly a third of US impressions are spent on content about ingredients the brand doesn’t sell (grape seed, borage oil, lycopene, dendrobium) that rank at dead positions 40–70 and never convert. To a small domain trying to be the deer-placenta authority, that spread reads as “unfocused” and holds back the pages that matter. Rebuilding a tight topical authority (pillar & supporting-cluster architecture) is a deliberate content-strategy build.
“Deer placenta benefits” is a health query, and Google’s 2025–2026 updates elevate credentialed, cited, expert health sources. Right now there’s little for Google to elevate: no named expert author, no medical/nutrition reviewer, no primary citations on claims, no original first-party evidence. This is precisely why the buying cluster ranks page 1–2 but not top 3 — and it’s a specialist content build, in a regulated category, that the client can’t safely self-serve.
The technical foundation is correctly set up for a Singapore-based manufacturer — that part is right, and it should stay. What’s missing for a US goal is a thin layer of explicit US-market signals on top: hreflang targeting, a small addition to the schema markup so the served market reads as the United States, and US-market content and trust cues. Google’s 2026 updates sort by user-market fit, so these additions tell Google “serve this to US searchers” — while the Singapore/HSA compliance stays exactly where it is, working as manufacturer credibility. A minor, additive refinement with an outsized effect on US eligibility.
As the site has evolved, several URLs that had built up genuine ranking history no longer map to a live page, so that accumulated equity isn’t being consolidated into the current pages. Reclaiming it — a redirect-equity audit that channels each legacy URL’s authority into the right live page — is a quick technical win that helps rebuild the lost reach from §02.
This is the reassuring part. You are not starting from zero — you already hold page-1 US positions on the commercial cluster. The bare head term is the lone outlier stuck on page 3. Fix the structure and the cluster climbs toward the top three.
US demand is 96.7% non-branded (5,618 impressions) — a large, unclaimed pool. When people already know the brand they convert at 47%. The gap is non-branded visibility plus a path to buy — both of which we control.
Here is the money insight. You rank well enough to pull thousands of readers — but they land on articles with no way to buy. They read, learn, and leave. This is a pure conversion leak, and closing it is high-ROI because the traffic already exists.
In practice the pop-up is subtle and reader-friendly: it waits until someone is genuinely engaged (a few seconds in, or as they move to leave), then offers a small first-order discount worded to match the article they’re reading — and once dismissed it stays gone. Paired with the in-article buy module, a reader can go from “learning about deer placenta” to “bought” without ever leaving the page.
Yes, and it’s the highest-ROI item here, for three reasons: (1) the traffic already exists — you’re paying the SEO cost and getting the readers, just not the sales; (2) matching the offer to the article’s intent converts far better than a generic banner; (3) more on-site engagement and conversions are themselves positive ranking signals, so it compounds with the SEO work.
The honest caveats: it’s a regulated supplement, so discount wording and any health framing must stay compliant; pop-ups must be tasteful (timing, frequency capping, mobile-friendly) or they hurt UX and SEO; and it should be measured with proper attribution, not vanity clicks. Done right, it’s low-risk. Done carelessly, it annoys — which is exactly why it’s a custom build, not an off-the-shelf plugin.
Ordered for impact-per-effort. Tags mark client-safe technical work vs. regulated-content work that needs sign-off. Each is real, and most are specialist builds — not something to DIY.
Swap “#1 for deer placenta” for a cluster + conversion KPI (below) and reconnect full analytics so every move is provable. Agree it up front so success is measured against something achievable.
Consolidate the deer-placenta cluster so the strong product page (position 4.5) becomes the page Google serves: canonical strategy, internal-link architecture, and anchor-text pointing the head/qualified terms at the product page instead of the homepage.
The custom system from §05: native in-article buy modules, topic-aware timed/exit offers, and a tracked discount-code workflow. Turns the ~99% of traffic that lands on articles into a real path to purchase.
Run the redirect-equity audit (§03.6): route every legacy URL’s authority into the right live cluster page. Quick, technical, and directly rebuilds lost reach.
Concentrate the site on deer placenta with a pillar-and-cluster content architecture; retire or consolidate the off-topic ingredient pages that dilute the signal.
Named expert author + medical/nutrition reviewer, primary citations on every claim, and original first-party evidence (NZ provenance, batch/assay proof, original media). Regulated category — claims routed for approval.
Deliberate international-SEO signals for the US (hreflang architecture, US market/entity signals, US-market trust), keeping the manufacturer’s compliance story as credibility rather than a Singapore-local signal.
Strengthen the Amazon presence so the brand shows where “best deer placenta supplement”-type queries surface shopping results the organic site can’t reach.
1 — Own US page-1 (target top-3) for the buying cluster: best deer placenta supplement (already 5.25), deer placenta benefits for women (6.72), deer placenta benefits (13.37 → top 5), deer placenta supplement (13.57 → page 1), deer placenta reviews (7.09).
2 — Make the product page the page Google serves — grow it from 48 toward 1,000+ US impressions at its page-1 position.
3 — Conversion from content: in-article add-to-cart rate and discount-code sales attributed to articles — the metric that turns rankings into revenue.
Not a target: position 1 for the bare phrase “deer placenta” — locked by research and marketplace results, and not achievable for any brand. Chasing it just manufactures the feeling of failure.
The rankings didn’t collapse — the site is under-monetising the visibility it already has, aimed partly at a term no brand can win, and leaking its best traffic at the point of purchase. Each of those is a lever, most need specialist work, and together they convert “why aren’t we #1” into a plan that grows both rankings and revenue.